Dataset Information

A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG⁺ hybridomas in comparison to its recombinant allergen-drug conjugate.

ABSTRACT:

Introduction

Current treatments for asthma help to alleviate clinical symptoms but do not cure the disease. In this study, we explored a novel therapeutic approach for the treatment of house dust mite allergen Der p 1induced asthma by aiming to eliminate specific population of B-cells involved in memory IgE response to Der p 1.

Materials and methods

To achieve this aim, we developed and evaluated two different proDer p 1-based fusion proteins; an allergen-toxin (proDer p 1-ETA) and an allergen-drug conjugate (ADC) (proDer p 1-SNAP-AURIF) against Der p 1 reactive hybridomas as an in vitro model for Der p 1 reactive human B-cells. The strategy involved the use of proDer p 1 allergen as a cell-specific ligand to selectively deliver the bacterial protein toxin Pseudomonas

SUBMITTER: Daramola AK

PROVIDER: S-EPMC9912260 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG⁺ hybridomas in comparison to its recombinant allergen-drug conjugate.

Introduction

Materials and methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG+ hybridomas in comparison to its recombinant allergen-drug conjugate.

Introduction

Materials and methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgG⁺ hybridomas in comparison to its recombinant allergen-drug conjugate.